A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Lampalizumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Acronyms Omaspect
- Sponsors Roche
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 Status changed from planning to not yet recruiting.
- 18 Sep 2014 New trial record